GRANITE-001 is a mrna vaccine commercialized by Gritstone Bio, with a leading Phase III program in Metastatic Colorectal Cancer. According to Globaldata, it is involved in 5 clinical trials, of which 2 were completed, 1 is ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of GRANITE-001’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for GRANITE-001 is expected to reach an annual total of $151 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
GRANITE-001 Overview
Gritstone Bio Overview
Gritstone Bio (Gritstone), formerly Gritstone Oncology, is a clinical-stage biotechnology company. The company discovers, develops, manufactures, and delivers vaccine-based immunotherapy candidates against cancer and infectious diseases. It develops personalized cancer vaccines designed to direct a robust immune response to neoantigens by leveraging its artificial intelligence Gritstone EDGE platform. Gritstone’s cancer vaccines product pipeline includes GRANITE and SLATE for solid tumors; and prophylactic samRNA (CORAL), HIV Therapeutic vaccine, and other flu, multi-respiratory, papillomavirus (HPV) eradication pathogens. The company designs immunotherapy containing the relevant neoantigens to be administered by intramuscular injection. It manufactures products through its biomanufacturing facilities in Massachusetts, and California, the US. Gritstone is headquartered in Emeryville, California, the US.
The company reported revenues of (US Dollars) US$16.3 million for the fiscal year ended December 2023 (FY2023), a decrease of 18.1% over FY2022. The operating loss of the company was US$139.6 million in FY2023, compared to an operating loss of US$120.4 million in FY2022. The net loss of the company was US$138.5 million in FY2023, compared to a net loss of US$119.7 million in FY2022.
The company reported revenues of US$1.7 million for the first quarter ended March 2024, a decrease of 83.2% over the previous quarter.
For a complete picture of GRANITE-001’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.